Core Points - DBV Technologies has filed an addendum to the 2024 Universal Registration Document with the French market authority AMF [1] - The addendum updates the Corporate Governance Report regarding exceptional compensation granted to the CEO, pending approval at the Annual Combined General Meeting on June 11, 2025 [2] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions with significant unmet medical needs [4] - The company utilizes its proprietary Viaskin technology platform to address food allergies through epicutaneous immunotherapy (EPIT™), which aims to desensitize the immune system to allergens [4] - Ongoing clinical trials include Viaskin Peanut for peanut allergic toddlers and children [4] Operations and Trading - DBV Technologies is headquartered in Châtillon, France, with operations in Warren, NJ, North America [5] - The company's ordinary shares are traded on Euronext Paris and its American Depositary Shares (ADSs) on the Nasdaq Capital Market [5]

Company Overview - DBV Technologies S.A. (DBVT) is a notable stock within the Medical sector, which consists of 999 companies and currently ranks 4 in the Zacks Sector Rank [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which includes 506 stocks and is ranked 70 in the Zacks Industry Rank [6] Performance Metrics - DBVT has experienced a year-to-date gain of approximately 210.7%, significantly outperforming the average loss of 4.4% in the Medical sector [4] - The Zacks Consensus Estimate for DBVT's full-year earnings has increased by 78.9% over the past quarter, indicating a positive shift in analyst sentiment [4] Comparison with Peers - Hims & Hers Health, Inc. (HIMS) is another Medical stock that has shown strong performance, with a year-to-date return of 153.1% and a Zacks Rank of 2 (Buy) [5] - The Medical Info Systems industry, to which HIMS belongs, has seen a year-to-date increase of 16.9%, contrasting with the performance of DBVT's industry [7]

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- ...

Core Points - DBV Technologies will hold its Combined General Meeting on June 11, 2025, at 02:00 p.m. CEST at its headquarters in Châtillon, France [1] - The preliminary notice with the detailed agenda and instructions for participation was published on May 07, 2025 [2] - Shareholders can access preparatory documents on the Company's website, in compliance with legal provisions [3] - Shareholders wishing to receive documents by post or electronically must request them by June 06, 2025 [4] - A live webcast of the General Meeting will be available on the Company's website, with a recorded version accessible for at least the minimum legal period [5] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions [6] - The Company utilizes its proprietary Viaskin technology platform to address food allergies through epicutaneous immunotherapy (EPIT™) [6] - DBV Technologies is conducting clinical trials for Viaskin Peanut in peanut allergic toddlers and children [6] - The Company is headquartered in Châtillon, France, with operations in Warren, NJ, and its shares are traded on Euronext Paris and Nasdaq [7]

Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [6] - The company is investigating the use of its proprietary technology platform, Viaskin, to address food allergies through epicutaneous immunotherapy (EPIT™) [6] - DBV Technologies is committed to transforming the care of individuals with food allergies, with ongoing clinical trials for Viaskin Peanut targeting peanut allergic toddlers and children [6] Upcoming General Meeting - The Combined General Meeting is scheduled for June 11, 2025, at 02:00 p.m. CEST at the company's headquarters in Châtillon, France [1] - A preliminary notice containing the detailed agenda and draft resolutions was published on May 07, 2025, and the official meeting notice will be published on May 21, 2025 [2] - Shareholders can access preparatory documents on the company's website, and requests for documents can be made until June 06, 2025 [3][4] Webcast Information - A live webcast of the General Meeting will be available on the company's website, with a recorded version accessible within seven business days after the meeting [5]

Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions with significant unmet medical needs [3][4] - The company is headquartered in Châtillon, France, with North American operations in Warren, NJ [4] Technology and Treatment Approach - DBV Technologies is investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by hypersensitive immune reactions [3] - The VIASKIN® patch is designed to introduce microgram amounts of biologically active compounds to the immune system through intact skin, utilizing epicutaneous immunotherapy (EPIT™) [3] - EPIT™ aims to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergens, leveraging the skin's immune tolerizing properties [3] Clinical Trials and Focus Areas - The company is currently conducting ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (ages 1 to 3) and children (ages 4 to 7) [3]

Exhibit 99.1 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the First Quarter of 2025. The quarterly and three months financial statements were approved by the Board of Directors on April 30, 2025. Financial Highlights for the First Quarter Ended March 31, 2025 The Company's interim condensed consolidated financial statements for the three months ended March 31, 2025, are p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________ FORM 10-Q ____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to _______________ Commission file number 001-36697 DBV TECHNOLOGIES S.A. (Exact name of registrant a ...

Core Viewpoint - DBV Technologies reported its financial results for the first quarter of 2025, highlighting significant cash usage in operations and ongoing clinical trials, while also announcing a financing plan to support its product development [1][5]. Financial Highlights - Cash and cash equivalents decreased to $13.0 million as of March 31, 2025, from $32.5 million at the end of 2024, reflecting a net decrease of $19.5 million, primarily due to $19.7 million used in operating activities [4][8]. - The company incurred operating losses and negative cash flows since inception, with no product revenue generated to date [6]. Cash Flow Analysis - The net cash flow used in operating activities was $19.7 million for Q1 2025, compared to $34.7 million for the same period in 2024, indicating an improvement in cash flow management [21]. - The company received gross proceeds of $125.5 million on April 7, 2025, as part of a financing plan of up to $306.9 million to support the Viaskin® Peanut Patch [5]. Operating Income and Expenses - Operating income for Q1 2025 was $0.8 million, down from $1.4 million in Q1 2024, attributed to a lower French Research Tax Credit due to more activities being conducted in North America [10][12]. - Total operating expenses decreased to $27.4 million in Q1 2025 from $30 million in Q1 2024, mainly due to reduced General & Administrative expenses [13][15]. Net Loss - The net loss for the first quarter of 2025 was $27.1 million, slightly improved from a net loss of $27.3 million in the same quarter of 2024 [16][17]. Financial Position - As of March 31, 2025, total assets were $50.6 million, down from $65.7 million at the end of 2024, with liabilities increasing to $47.7 million from $38.3 million [18]. Company Overview - DBV Technologies is focused on developing treatment options for food allergies using its proprietary Viaskin technology, which aims to provide non-invasive immunotherapy [22]. - The company is currently conducting clinical trials for its Viaskin Peanut product targeting peanut allergies in young children [22].